<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Wed, 27 May 2026 16:16:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Form  SD         PACIFIC BIOSCIENCES OF               </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++PACIFIC+BIOSCIENCES+OF+++++++++++++++/26558105.html</link>
   <description>si-local-file:///var/storage/secattach/20260527/26558105.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++PACIFIC+BIOSCIENCES+OF+++++++++++++++/26558105.html</guid>
   <pubDate>Wed, 27 May 2026 16:16:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Form  SD         PACIFIC BIOSCIENCES OF               </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++PACIFIC+BIOSCIENCES+OF+++++++++++++++/26558105.html</link>
   <description>si-local-file:///var/storage/secattach/20260527/26558105.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++PACIFIC+BIOSCIENCES+OF+++++++++++++++/26558105.html</guid>
   <pubDate>Wed, 27 May 2026 16:16:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>PacBio begins shipping SPRQ-Nx chemistry to reduce genome costs</title>
   <link>http://www.streetinsider.com/Corporate+News/PacBio+begins+shipping+SPRQ-Nx+chemistry+to+reduce+genome+costs/26546899.html</link>
   <description>&lt;p&gt;PacBio (NASDAQ: PACB) announced the global shipment of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio HiFi sequencing platform. The company stated the technology brings the per genome list price to $345, with the possibility of sub-$300 HiFi genomes for customers sequencing at scale.&lt;/p&gt;&lt;p&gt;The new chemistry allows SMRT Cell consumables to be used multiple times, according to the company. PacBio reported that beta testing across 20 sites in Europe, Asia, and the United States, spanning over 1,400 runs, showed increased yield and lower failure rates compared to its previous SPRQ chemistry.&lt;/p&gt;&lt;p&gt;The company also announced updates to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Corporate+News/PacBio+begins+shipping+SPRQ-Nx+chemistry+to+reduce+genome+costs/26546899.html</guid>
   <pubDate>Tue, 26 May 2026 09:06:34 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing</title>
   <link>http://www.streetinsider.com/Press+Releases/PacBio+SPRQ-Nx+Chemistry+Now+Shipping+Worldwide%2C+Enabling+Sub-%24300+HiFi+Genomes+for+Large+Scale+Projects+and+AI-Enhanced+Sequencing/26546878.html</link>
   <description>
&lt;p&gt;MENLO PARK, Calif., May  26, 2026  (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced that SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for its Revio HiFi sequencing platform are now shipping worldwide. The commercial availability of SPRQ-Nx brings the per genome list price to $345, and the possibility of sub-$300 HiFi genomes to Revio customers sequencing at scale1, while expanded methylation detection and advances to DeepConsensus, an AI powered consensus algorithm developed in collaboration with Google, further improve accuracy, run performance, and the biological information generated from each read.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/PacBio+SPRQ-Nx+Chemistry+Now+Shipping+Worldwide%2C+Enabling+Sub-%24300+HiFi+Genomes+for+Large+Scale+Projects+and+AI-Enhanced+Sequencing/26546878.html</guid>
   <pubDate>Tue, 26 May 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing</title>
   <link>http://www.streetinsider.com/Press+Releases/PacBio+SPRQ-Nx+Chemistry+Now+Shipping+Worldwide%2C+Enabling+Sub-%24300+HiFi+Genomes+for+Large+Scale+Projects+and+AI-Enhanced+Sequencing/26546878.html</link>
   <description>
&lt;p&gt;MENLO PARK, Calif., May  26, 2026  (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced that SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for its Revio HiFi sequencing platform are now shipping worldwide. The commercial availability of SPRQ-Nx brings the per genome list price to $345, and the possibility of sub-$300 HiFi genomes to Revio customers sequencing at scale1, while expanded methylation detection and advances to DeepConsensus, an AI powered consensus algorithm developed in collaboration with Google, further improve accuracy, run performance, and the biological information generated from each read.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/PacBio+SPRQ-Nx+Chemistry+Now+Shipping+Worldwide%2C+Enabling+Sub-%24300+HiFi+Genomes+for+Large+Scale+Projects+and+AI-Enhanced+Sequencing/26546878.html</guid>
   <pubDate>Tue, 26 May 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing</title>
   <link>http://www.streetinsider.com/Globe+Newswire/PacBio+SPRQ-Nx+Chemistry+Now+Shipping+Worldwide%2C+Enabling+Sub-%24300+HiFi+Genomes+for+Large+Scale+Projects+and+AI-Enhanced+Sequencing/26546878.html</link>
   <description>
&lt;p&gt;MENLO PARK, Calif., May  26, 2026  (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced that SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for its Revio HiFi sequencing platform are now shipping worldwide. The commercial availability of SPRQ-Nx brings the per genome list price to $345, and the possibility of sub-$300 HiFi genomes to Revio customers sequencing at scale1, while expanded methylation detection and advances to DeepConsensus, an AI powered consensus algorithm developed in collaboration with Google, further improve accuracy, run performance, and the biological information generated from each read.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/PacBio+SPRQ-Nx+Chemistry+Now+Shipping+Worldwide%2C+Enabling+Sub-%24300+HiFi+Genomes+for+Large+Scale+Projects+and+AI-Enhanced+Sequencing/26546878.html</guid>
   <pubDate>Tue, 26 May 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing</title>
   <link>http://www.streetinsider.com/Globe+Newswire/PacBio+SPRQ-Nx+Chemistry+Now+Shipping+Worldwide%2C+Enabling+Sub-%24300+HiFi+Genomes+for+Large+Scale+Projects+and+AI-Enhanced+Sequencing/26546878.html</link>
   <description>
&lt;p&gt;MENLO PARK, Calif., May  26, 2026  (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced that SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for its Revio HiFi sequencing platform are now shipping worldwide. The commercial availability of SPRQ-Nx brings the per genome list price to $345, and the possibility of sub-$300 HiFi genomes to Revio customers sequencing at scale1, while expanded methylation detection and advances to DeepConsensus, an AI powered consensus algorithm developed in collaboration with Google, further improve accuracy, run performance, and the biological information generated from each read.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/PacBio+SPRQ-Nx+Chemistry+Now+Shipping+Worldwide%2C+Enabling+Sub-%24300+HiFi+Genomes+for+Large+Scale+Projects+and+AI-Enhanced+Sequencing/26546878.html</guid>
   <pubDate>Tue, 26 May 2026 09:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Form  DEFA14A    PACIFIC BIOSCIENCES OF               </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++PACIFIC+BIOSCIENCES+OF+++++++++++++++/26542583.html</link>
   <description>si-local-file:///var/storage/secattach/20260522/26542583.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++PACIFIC+BIOSCIENCES+OF+++++++++++++++/26542583.html</guid>
   <pubDate>Fri, 22 May 2026 16:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Form  DEFA14A    PACIFIC BIOSCIENCES OF               </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++PACIFIC+BIOSCIENCES+OF+++++++++++++++/26542583.html</link>
   <description>si-local-file:///var/storage/secattach/20260522/26542583.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++PACIFIC+BIOSCIENCES+OF+++++++++++++++/26542583.html</guid>
   <pubDate>Fri, 22 May 2026 16:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>PacBio to Participate in the Jefferies Global Healthcare Conference </title>
   <link>http://www.streetinsider.com/Press+Releases/PacBio+to+Participate+in+the+Jefferies+Global+Healthcare+Conference%C2%A0/26535125.html</link>
   <description>
&lt;p&gt;MENLO PARK, Calif., May  21, 2026  (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies’ Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.&lt;/p&gt;  &lt;p&gt;A live webcast of the event can be accessed at the company’s investors page at &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=1yF0DM6ndIllaBESb4mp1ccxhmLn8g6R0qwxzvvOVkZ-Hk9sYiytYOYtO8qHSG3IeRYwHIHfszLsseZR2Zet_GowMO2cEhq49fxzuffBWXZbGlBarcxRVDqU20VkWdJ0oMaqAM3ZxDkUxYn822Q-ow==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;investor.pacificbiosciences.com&lt;/a&gt;. A replay of the webcast will be available for at least 30 days following the event.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;About PacBio&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;PacBio (NASDAQ: PACB) is a premier</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/PacBio+to+Participate+in+the+Jefferies+Global+Healthcare+Conference%C2%A0/26535125.html</guid>
   <pubDate>Thu, 21 May 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>PacBio to Participate in the Jefferies Global Healthcare Conference </title>
   <link>http://www.streetinsider.com/Press+Releases/PacBio+to+Participate+in+the+Jefferies+Global+Healthcare+Conference%C2%A0/26535125.html</link>
   <description>
&lt;p&gt;MENLO PARK, Calif., May  21, 2026  (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies’ Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.&lt;/p&gt;  &lt;p&gt;A live webcast of the event can be accessed at the company’s investors page at &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=1yF0DM6ndIllaBESb4mp1ccxhmLn8g6R0qwxzvvOVkZ-Hk9sYiytYOYtO8qHSG3IeRYwHIHfszLsseZR2Zet_GowMO2cEhq49fxzuffBWXZbGlBarcxRVDqU20VkWdJ0oMaqAM3ZxDkUxYn822Q-ow==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;investor.pacificbiosciences.com&lt;/a&gt;. A replay of the webcast will be available for at least 30 days following the event.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;About PacBio&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;PacBio (NASDAQ: PACB) is a premier</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/PacBio+to+Participate+in+the+Jefferies+Global+Healthcare+Conference%C2%A0/26535125.html</guid>
   <pubDate>Thu, 21 May 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>PacBio to Participate in the Jefferies Global Healthcare Conference </title>
   <link>http://www.streetinsider.com/Globe+Newswire/PacBio+to+Participate+in+the+Jefferies+Global+Healthcare+Conference%C2%A0/26535125.html</link>
   <description>
&lt;p&gt;MENLO PARK, Calif., May  21, 2026  (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies’ Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.&lt;/p&gt;  &lt;p&gt;A live webcast of the event can be accessed at the company’s investors page at &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=1yF0DM6ndIllaBESb4mp1ccxhmLn8g6R0qwxzvvOVkZ-Hk9sYiytYOYtO8qHSG3IeRYwHIHfszLsseZR2Zet_GowMO2cEhq49fxzuffBWXZbGlBarcxRVDqU20VkWdJ0oMaqAM3ZxDkUxYn822Q-ow==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;investor.pacificbiosciences.com&lt;/a&gt;. A replay of the webcast will be available for at least 30 days following the event.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;About PacBio&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;PacBio (NASDAQ: PACB) is a premier</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/PacBio+to+Participate+in+the+Jefferies+Global+Healthcare+Conference%C2%A0/26535125.html</guid>
   <pubDate>Thu, 21 May 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>PacBio to Participate in the Jefferies Global Healthcare Conference </title>
   <link>http://www.streetinsider.com/Globe+Newswire/PacBio+to+Participate+in+the+Jefferies+Global+Healthcare+Conference%C2%A0/26535125.html</link>
   <description>
&lt;p&gt;MENLO PARK, Calif., May  21, 2026  (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies’ Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.&lt;/p&gt;  &lt;p&gt;A live webcast of the event can be accessed at the company’s investors page at &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=1yF0DM6ndIllaBESb4mp1ccxhmLn8g6R0qwxzvvOVkZ-Hk9sYiytYOYtO8qHSG3IeRYwHIHfszLsseZR2Zet_GowMO2cEhq49fxzuffBWXZbGlBarcxRVDqU20VkWdJ0oMaqAM3ZxDkUxYn822Q-ow==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;investor.pacificbiosciences.com&lt;/a&gt;. A replay of the webcast will be available for at least 30 days following the event.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;About PacBio&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;PacBio (NASDAQ: PACB) is a premier</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/PacBio+to+Participate+in+the+Jefferies+Global+Healthcare+Conference%C2%A0/26535125.html</guid>
   <pubDate>Thu, 21 May 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
  <item>
   <title>Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology</title>
   <link>http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    SAN FRANCISCO--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.blank.bio&amp;amp;esheet=54535717&amp;amp;newsitemid=20260513274683&amp;amp;lan=en-US&amp;amp;anchor=Blank+Bio&amp;amp;index=1&amp;amp;md5=745973cb9e225ca03af344ca9996bb25&quot; shape=&quot;rect&quot;&gt;Blank Bio&lt;/a&gt;, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Blank+Bio+Announces+Seed+Financing+and+Strategic+Collaboration+with+PacBio+to+Advance+RNA+Foundation+Models+for+Precision+Oncology/26518350.html</guid>
   <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.18160122</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.36601769</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01128999</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08506358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.26335464</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PACB</category>
   	  </item>
 </channel>
</rss>
